Dr. Falk - Renexxion


Today, Renexxion and Dr. Falk Pharma announced a licensing and collaboration agreement to jointly develop and commercialize Naronapride.
Naronapride, a GI prokinetic with a unique target profile, has the potential to be the first-in-class treatment for gastroparesis, a disorder which does not currently have approved treatments.
Read the entire press release